Literature DB >> 3315284

Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

U Schuler1, G Ehninger, T Wagner.   

Abstract

Blood levels of cyclophosphamide (CP) and activated metabolites were measured in 11 patients undergoing a 2- to 4-day conditioning chemotherapy for bone marrow transplantation. Urinary excretion of CP was determined in five patients. CP half-life decreased after pretreatment from an average of 7.1 h on the 1st day to 5.5 h on the 2nd day (P less than 0.005) and to 4.3 h on the 4th day (P less than 0.005). No characteristic changes in urinary excretion could be observed. At the same time the exposure to non-protein-bound activated metabolites increased from 10.5 to 19.5 and 26.0 nmol x h/ml respectively (P less than 0.005 and P less than 0.04). Thus, in contrast to in vitro and animal studies, no evidence for an inhibition of activating enzymes could be found. On the contrary, pretreatment seems to enhance the production of the cytotoxic metabolites. The possible explanation of these changes by enzyme induction and by the role of saturated protein binding sites is discussed. Exposure to active metabolites might be altered by dose splitting or even by a change in the duration of the infusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315284     DOI: 10.1007/BF00570495

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

2.  [On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

Authors:  G Voelcker; H P Giera; L Jäger; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

3.  Fluorometric determination of acrolein and related compounds with m-aminophenol.

Authors:  R A Alarcon
Journal:  Anal Chem       Date:  1968-09       Impact factor: 6.986

4.  [Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models (author's transl)].

Authors:  G Heinzel; R Hammer; M Wolf; F W Koss; G Bozler
Journal:  Arzneimittelforschung       Date:  1977

5.  Allogeneic marrow grafting for treatment of aplastic anemia.

Authors:  R Storb; E D Thomas; C D Buckner; R A Clift; F L Johnson; A Fefer; H Glucksberg; E R Giblett; K G Lerner; P Neiman
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

6.  Studies of the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations and conjugations.

Authors:  H L Gurtoo; T Gessner; P Culliton
Journal:  Cancer Treat Rep       Date:  1976-09

7.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Decreased plasma half-life of cyclophosphamide during repeated high-dose administration.

Authors:  M I Graham; I C Shaw; R L Souhami; B Sidau; P G Harper; A E McLean
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Protective role of thiols in cyclophosphamide-induced urotoxicity and depression of hepatic drug metabolism.

Authors:  M J Berrigan; A J Marinello; Z Pavelic; C J Williams; R F Struck; H L Gurtoo
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

10.  Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.

Authors:  N E Sladek; D Doeden; J F Powers; W Krivit
Journal:  Cancer Treat Rep       Date:  1984-10
View more
  13 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.

Authors:  R L Souhami; H T Hajichristou; D W Miles; H M Earl; P G Harper; C M Ash; A H Goldstone; S G Spiro; D M Geddes; J S Tobias
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation.

Authors:  C Twelves; R Souhami; P Harper; A Goldstone
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

5.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

6.  Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

Authors:  W Linkesch; M Weger; I Eder; H W Auner; C Pernegg; C Kraule; M J Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

7.  Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients.

Authors:  U Schuler; P Waidelich; H Kolb; T Wagner; G Ehninger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Metabolism and pharmacokinetics of oral and intravenous ifosfamide.

Authors:  V Kurowski; T Cerny; A Küpfer; T Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 9.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

10.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.